How to Evaluate Telehealth for Low Testosterone

By
Published Updated Last reviewed
Prescription access and medication affordability image for How to Evaluate Telehealth for Low Testosterone

At a glance

  • Diagnostic threshold / total testosterone <300 ng/dL on two separate morning draws (Endocrine Society guideline)
  • Symptom requirement / low libido, fatigue, or erectile dysfunction must be documented before prescribing
  • Key baseline labs / total T, free T, LH, FSH, PSA, CBC, estradiol, hematocrit, metabolic panel
  • Monitoring frequency / every 3 months in year one, then every 6 to 12 months once stable
  • Hematocrit safety cutoff / hold or reduce dose if hematocrit exceeds 54%
  • PSA watch / recheck PSA at 3 to 6 months; rise >1.4 ng/mL above baseline warrants urology referral
  • Prevalence / roughly 2.1% of men aged 30 to 79 meet criteria for symptomatic hypogonadism (Araujo et al., J Clin Endocrinol Metab 2007)
  • Fertility flag / exogenous testosterone suppresses spermatogenesis; HCG or clomiphene co-therapy is standard if fertility is desired

Why the Diagnostic Standard Matters Before You Pick a Platform

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." [1] That sentence defines the legal and clinical minimum any telehealth provider must clear.

Low testosterone is not a lifestyle upgrade. It is a medical diagnosis. A platform that prescribes testosterone based on a single questionnaire, a fingerstick test, or a venous draw taken at any time of day fails the first test of legitimacy.

What "Two Morning Draws" Actually Means

Total testosterone follows a circadian rhythm, peaking between 7 a.m. And 10 a.m. And falling by as much as 30% by afternoon. [2] A single afternoon value of 280 ng/dL does not confirm hypogonadism. The Endocrine Society guideline requires confirmation on a second sample drawn on a separate morning before initiating therapy. [1]

Ask any prospective telehealth platform directly: "Do you require two separate fasting morning testosterone measurements before prescribing?" If the answer is no, move on.

Free Testosterone and When It Changes the Picture

Total testosterone alone misses about 15 to 20% of men with symptomatic hypogonadism because sex-hormone-binding globulin (SHBG) levels vary widely. [3] Men with obesity, hypothyroidism, or older age often have altered SHBG, making free testosterone the more clinically relevant number. A reputable platform calculates free testosterone either by equilibrium dialysis or the Vermeulen equation when total testosterone sits in the borderline 300 to 400 ng/dL range.

What Baseline Labs a Legitimate Platform Must Order

Good telehealth TRT is not a testosterone-only conversation. The same 2018 Endocrine Society guideline recommends ruling out secondary causes and establishing safety baselines before the first injection or application. [1]

The Required Panel

A credible platform orders all of the following before prescribing:

  • Total testosterone (morning, fasting, two separate draws)
  • Free testosterone (especially if total is 300 to 400 ng/dL or SHBG is suspected to be abnormal)
  • LH and FSH (to distinguish primary from secondary hypogonadism)
  • PSA (prostate-specific antigen, required for men over 40 per FDA labeling) [4]
  • CBC with hematocrit (testosterone raises red-cell mass; baseline hematocrit above 48% may contraindicate therapy)
  • Estradiol (baseline needed to manage aromatization on therapy)
  • Comprehensive metabolic panel (liver function, glucose, kidney function)
  • Prolactin (elevated prolactin suggests a pituitary adenoma, a contraindication to TRT without further workup) [1]

Any platform that omits LH, FSH, and prolactin from the baseline draw is not performing a diagnostic workup. It is selling testosterone.

Why LH and FSH Change the Treatment Plan

Secondary hypogonadism (low LH, low testosterone) in a man who wants future fertility should not be treated with exogenous testosterone. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and sperm production. [5] In that case, clomiphene citrate 25 to 50 mg every other day or human chorionic gonadotropin (HCG) 500 to 1,000 IU three times per week maintains fertility while raising serum testosterone. A telehealth platform that never asks about fertility and reflexively prescribes injectable testosterone cypionate to every patient is a red flag.

How to Read a Telehealth TRT Provider's Monitoring Protocol

Prescribing testosterone without a monitoring plan is like starting a patient on warfarin without INR checks. The FDA-approved labeling for testosterone cypionate injection explicitly lists hematocrit elevation, PSA changes, and cardiovascular risk as required monitoring parameters. [4]

What Year-One Monitoring Should Look Like

The American Urological Association's 2018 testosterone deficiency guideline recommends the following schedule in year one of therapy: [6]

  1. Labs at 3 months post-initiation: total testosterone (trough for injections, mid-cycle for weekly injections), hematocrit, PSA
  2. Labs at 6 months: repeat full panel including estradiol and CBC
  3. Labs at 12 months: full panel plus bone density consideration if osteoporosis risk is present

Any telehealth platform that offers annual-only monitoring during the first year does not meet this standard.

The Hematocrit Rule

Testosterone stimulates erythropoiesis. A hematocrit above 54% raises thrombotic risk. The Endocrine Society guideline and FDA labeling both specify that therapy should be withheld or the dose reduced when hematocrit exceeds this threshold. [1][4] Patients on testosterone cypionate 200 mg every two weeks have higher hematocrit excursions than patients on 100 mg weekly because of the supraphysiologic peak-and-trough pattern. A quality platform adjusts dosing intervals to minimize those peaks.

PSA Monitoring and Prostate Safety

Testosterone does not cause prostate cancer, but it may stimulate growth of an undetected cancer. The FDA label for testosterone products requires PSA measurement at 3 to 6 months after initiating therapy. [4] A PSA rise of more than 1.4 ng/mL above the baseline value within any 12-month period, or a PSA above 4.0 ng/mL at any point, warrants urology referral before continuing therapy. Any platform that does not address PSA in its protocol is not compliant with the product's approved labeling.

Comparing Telehealth TRT Delivery Formats

Testosterone is approved by the FDA in several formulations. Each has different pharmacokinetics, monitoring demands, and patient-experience trade-offs. [4]

Injectable Testosterone Cypionate and Enanthate

Testosterone cypionate (100 to 200 mg intramuscularly or subcutaneously every 7 to 14 days) remains the most prescribed format in telehealth due to low cost, roughly $30 to 60/month for the medication itself. Weekly subcutaneous injections of 70 to 100 mg produce more stable serum levels than biweekly intramuscular dosing and reduce hematocrit spikes. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, followed men with hypogonadism and cardiovascular risk for a mean of 33 months on testosterone gel and found a cardiovascular event rate of 7.0% versus 7.3% on placebo, establishing non-inferiority for cardiovascular safety in men without recent cardiac events. [7]

Topical Gels and Creams

Testosterone 1% gel (AndroGel, generic equivalents) and compounded testosterone cream are applied daily, avoiding injection anxiety. Transfer risk to partners and children is a real concern with gels; patients must wash hands and cover application sites. Compounded testosterone cream at 10 to 20% concentration in a lipoderm base is widely used by telehealth platforms but is not FDA-approved as a finished product. The quality of compounded formulations depends on the compounding pharmacy's USP 795/797 compliance. [8]

Pellet Therapy

Subcutaneous pellets (Testopel, 75 mg per pellet, typically 8 to 12 pellets every 3 to 6 months) are inserted in-office or at a clinic partner. Telehealth platforms that offer pellets must have a physical-location partner network. Pellet dosing is fixed once inserted; unlike injections or gels, the dose cannot be quickly adjusted if hematocrit rises or the patient experiences adverse effects.

Red Flags That Disqualify a Telehealth TRT Provider

The following practices place a platform outside evidence-based care. Each alone is reason to find a different provider.

Prescribing Without a Confirmed Diagnosis

Any platform that skips the two-draw confirmation rule or does not document consistent symptoms alongside low testosterone values is not diagnosing hypogonadism. It is filling an order. This matters clinically because roughly 25% of men who report classic low-T symptoms have normal testosterone levels, according to data from the Boston Area Community Health survey analyzed by Araujo et al. [9] Treating those men with testosterone exposes them to side effects with no expected benefit.

No Physician or NP/PA Oversight

The DEA classifies testosterone as a Schedule III controlled substance. Prescriptions require a licensed prescriber with a valid DEA registration. Platforms that use "health coaches" or algorithms to generate prescriptions without physician review are operating outside federal law. Confirm that a board-certified physician (ideally in urology, endocrinology, or internal medicine) reviews every chart before a prescription is issued.

Unlimited Refills With No Lab Requirement

A refill policy that ships testosterone indefinitely without requiring updated hematocrit, PSA, or testosterone levels is dangerous. Polycythemia from unchecked testosterone use has caused pulmonary embolism and stroke. [10] The FDA label for every testosterone product requires periodic monitoring. [4]

High-Pressure Upsell of Unproven Add-ons

Some platforms automatically bundle testosterone with growth-hormone secretagogues (sermorelin, ipamorelin), DHEA, or anastrozole without clinical indication. Anastrozole is a breast-cancer drug used off-label to suppress estrogen in TRT patients; routine prescription without documented high estradiol and symptoms of estrogen excess is not supported by the Endocrine Society guideline. [1]

Cost Evaluation: What You Should Actually Pay

Telehealth TRT costs vary widely. Here is a realistic breakdown by component.

| Cost Component | Reasonable Range | Red-Flag Pricing | |---|---|---| | Initial consultation | $50, $150 | $0 (loss-leader for high-margin meds) | | Baseline lab panel (full) | $150, $400 at LabCorp/Quest | "Free labs" bundled into inflated med cost | | Monthly medication (cypionate generic) | $30, $80 | Over $200/month for generic injectable | | Quarterly monitoring labs | $80, $200 | No lab requirement at all | | Annual physician follow-up | $75, $150/visit | Async-only with no live visit option |

A full first-year cost for properly managed telehealth TRT, including labs and consultations, typically runs $800, $1,800 depending on formulation. Platforms advertising $99/month all-inclusive without specifying what labs are included should be scrutinized carefully for what monitoring is being skipped.

Questions to Ask Any Telehealth TRT Provider Before You Enroll

Direct questions get direct answers. Use this list before you provide payment information.

  1. Do you require two separate morning testosterone draws before prescribing?
  2. Does your baseline panel include LH, FSH, prolactin, PSA, and CBC?
  3. Who reviews my labs, and what is their specialty and licensure?
  4. What is your protocol if my hematocrit exceeds 54%?
  5. How do you handle PSA increases above 1.4 ng/mL during therapy?
  6. What is your policy on fertility preservation if I want children?
  7. Can I reach a prescriber by phone or video within 48 hours if I have a side effect?
  8. Do you use an FDA-registered 503B compounding pharmacy, or do you dispense FDA-approved finished products?

A platform that cannot answer questions 1, 2, 4, and 5 with specific numerical thresholds is not operating a medical-grade TRT program.

Understanding the Cardiovascular Evidence

For years, TRT's cardiovascular safety was genuinely uncertain. Two studies published around 2010 raised concern, but had significant methodological limitations. [11] The TRAVERSE trial resolved much of that uncertainty.

TRAVERSE Trial Results

TRAVERSE (N=5,246, mean follow-up 33 months) enrolled men aged 45 to 80 with hypogonadism (two testosterone values <300 ng/dL) and either pre-existing cardiovascular disease or elevated cardiovascular risk. The primary endpoint, a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, occurred in 7.0% of testosterone-treated men versus 7.3% of placebo patients (hazard ratio 0.96; 95% CI 0.78 to 1.17), meeting the pre-specified non-inferiority margin. [7] Atrial fibrillation was more common in the testosterone group (3.5% vs. 2.4%, P<0.001). Pulmonary embolism occurred in 0.9% of testosterone patients versus 0.5% on placebo.

These findings mean TRT is cardiovascularly non-inferior in this population, but not risk-free. Men with a history of venous thromboembolism or atrial fibrillation require individualized risk discussion before starting therapy.

What TRAVERSE Does Not Cover

TRAVERSE used testosterone gel (AndroGel 1.62%). The findings may not fully generalize to high-dose injectable protocols that create supraphysiologic peaks. Men on injectable testosterone with hematocrit above 50% were not the studied population, and the thromboembolic signal in TRAVERSE was real enough to warrant caution in high-risk patients.

Confirming a Telehealth Platform's Pharmacy Standards

Testosterone cypionate is available as an FDA-approved finished product (Watson/Actavis generics) and as compounded formulations from 503A and 503B pharmacies. [8]

FDA-approved finished products carry the highest quality assurance. Compounded products from 503B outsourcing facilities are subject to FDA inspection and current Good Manufacturing Practice (cGMP) standards, making them the acceptable alternative when the commercial product is on shortage or a non-standard concentration is needed. Compounded products from 503A pharmacies are patient-specific and have less federal oversight.

Ask your telehealth platform to name the pharmacy it uses and confirm its 503A or 503B status on the FDA's registered outsourcing facilities list. [8] This is not an administrative detail. Contaminated compounded steroids have caused serious adverse events, including the 2012 fungal meningitis outbreak linked to a non-compliant compounding pharmacy that killed 64 people. [12]

Using Lab Reference Ranges Correctly

Not all labs use the same reference range for testosterone. LabCorp's current lower reference limit for adult men is 264 ng/dL; Quest Diagnostics uses 250 ng/dL. Neither of these laboratory cutoffs is identical to the clinical diagnostic threshold.

The Endocrine Society uses 300 ng/dL as the lower threshold for clinical hypogonadism. [1] A total testosterone of 275 ng/dL is technically within some laboratory reference ranges but below the clinical diagnostic threshold. A reputable telehealth platform interprets results against the 300 ng/dL clinical standard, not just the lab's printed "normal" range.

Free testosterone reference ranges vary even more widely depending on the assay method. Equilibrium dialysis is the gold-standard method; immunoassay-based free testosterone is less accurate and overestimates free testosterone in men with low SHBG. [3] Ask which assay method the platform's lab uses.

Frequently asked questions

›How do I evaluate a telehealth provider for low testosterone?
Confirm the platform requires two fasting morning total testosterone draws below 300 ng/dL before prescribing, documents symptoms like low libido or fatigue, orders a baseline panel including LH, FSH, PSA, CBC, and estradiol, and has a licensed physician (not just a health coach) review every chart. Monitoring labs every 3 months in year one, including hematocrit and PSA, are the minimum standard per the Endocrine Society and AUA guidelines.
›What testosterone level qualifies for TRT?
The Endocrine Society guideline sets the diagnostic threshold at total testosterone below 300 ng/dL on two separate morning draws, combined with consistent symptoms such as low libido, fatigue, erectile dysfunction, or loss of muscle mass. A low lab value alone, without documented symptoms, is not sufficient for diagnosis.
›Is telehealth TRT as safe as in-person TRT?
Safety depends on the monitoring protocol, not the delivery channel. Telehealth TRT that includes two diagnostic draws, full baseline labs, quarterly hematocrit and PSA checks, and physician oversight meets the same standard as in-person care. Telehealth TRT that skips these steps is less safe regardless of convenience.
›What labs should a telehealth TRT provider order before starting therapy?
The minimum baseline panel is: total testosterone (two morning draws), free testosterone, LH, FSH, prolactin, PSA (for men over 40), CBC with hematocrit, estradiol, and a comprehensive metabolic panel. Platforms that omit LH, FSH, or prolactin are not performing a complete diagnostic workup.
›How often should I get labs while on telehealth TRT?
Every 3 months for the first year of therapy, then every 6 to 12 months once levels are stable. Each monitoring draw should include total testosterone, hematocrit, PSA, and estradiol at minimum. This schedule follows the American Urological Association's 2018 testosterone deficiency guideline.
›Can telehealth prescribe testosterone if I want to have children?
Exogenous testosterone suppresses sperm production and should not be prescribed as the primary treatment for men who want future fertility. A reputable telehealth platform will ask about fertility goals and offer alternatives such as clomiphene citrate or HCG, which raise testosterone without shutting down spermatogenesis.
›What are the red flags of a bad telehealth TRT provider?
Key red flags include prescribing from a single draw or questionnaire alone, no requirement for LH or FSH, no PSA check before starting, no hematocrit monitoring protocol, no licensed physician reviewing charts, unlimited refills with no lab requirement, and pressure to add unproven supplements or unapproved peptides without clinical indication.
›Is testosterone from a telehealth compounding pharmacy safe?
Compounded testosterone from an FDA-registered 503B outsourcing facility meets federal cGMP standards and is an acceptable option when commercial products are unavailable. Compounded products from 503A pharmacies carry less federal oversight. Ask your platform to name its pharmacy and verify its FDA registration status before filling a prescription.
›Does TRT cause heart attacks?
The TRAVERSE trial (N=5,246, mean follow-up 33 months) found that testosterone gel was non-inferior to placebo for the composite cardiovascular endpoint of death, myocardial infarction, and stroke (7.0% vs. 7.3%, HR 0.96). Atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) were more common with testosterone. Men with prior venous thromboembolism or atrial fibrillation require individualized risk discussion.
›How much does telehealth TRT cost per month?
Medication cost for generic testosterone cypionate typically runs $30 to $80 per month. Adding quarterly monitoring labs ($80 to $200 per draw) and periodic consultations, a realistic first-year total is $800 to $1,800 depending on formulation and platform. Platforms advertising all-inclusive plans under $99/month should be asked specifically what monitoring labs are included.
›What is a normal testosterone level for a man?
Most laboratories place the adult male reference range between 250 and 1,100 ng/dL, but the clinical threshold for diagnosing hypogonadism is below 300 ng/dL per the Endocrine Society guideline. Men with values between 300 and 400 ng/dL and significant symptoms may still qualify for therapy if free testosterone is also low.

References

  1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
  2. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907-913. https://pubmed.ncbi.nlm.nih.gov/19088162/
  3. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672. https://pubmed.ncbi.nlm.nih.gov/10523012/
  4. U.S. Food and Drug Administration. Testosterone Cypionate Injection, USP, Prescribing Information. FDA. Accessed January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/085635s033lbl.pdf
  5. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602. https://pubmed.ncbi.nlm.nih.gov/15687326/
  6. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29601923/
  7. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37326322/
  8. U.S. Food and Drug Administration. Registered Outsourcing Facilities (503B). FDA. Accessed January 2025. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  9. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-4247. https://pubmed.ncbi.nlm.nih.gov/17726077/
  10. Glueck CJ, Wang P. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism. 2014;63(8):989-994. https://pubmed.ncbi.nlm.nih.gov/24930993/
  11. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122. https://pubmed.ncbi.nlm.nih.gov/20592293/
  12. Centers for Disease Control and Prevention. Multistate Fungal Meningitis Outbreak, United States, 2012. MMWR. 2013;62(29):585-587. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6229a4.htm